ERBB2 and breast cancer: Multivariate analysis revealed that patients with early diagnosis years, aged >70 years, and with luminal-B–like (HER2-positive) breast cancer were less likely to adhere to the endocrine therapy recommendation (Table S8 in Multimedia Appendix 1).